Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2021 Jan 9

PMID 33419944

Citations 15

Authors

Andreas G Wibmer

Michael J Morris

Mithat Gonen

Junting Zheng

Hedvig Hricak

Steven Larson

Howard I Scher

Hebert Alberto Vargas

Affiliations

Soon will be listed here.

Abstract

New biomarkers for metastatic prostate cancer are needed. The aim of this study was to evaluate the prognostic value of F-FDG PET whole-body tumor burden parameters in patients with metastatic prostate cancer who received first-line abiraterone or enzalutamide therapy. This was a retrospective study of patients with metastatic castration-sensitive prostate cancer (mCSPC, = 25) and metastatic castration-resistant prostate cancer (mCRPC, = 71) who underwent F-FDG PET/CT within 90 d before first-line treatment with abiraterone or enzalutamide at a tertiary-care academic cancer center. Whole-body tumor burden on PET/CT was quantified as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) and correlated with overall survival (OS) probabilities using Kaplan-Meier curves and Cox models. The median follow-up in survivors was 56.3 mo (interquartile range, 37.7-66.8 mo); the median OSs for patients with mCRPC and mCSPC were 27.8 and 76.1 mo, respectively ( < 0.001). On univariate analysis, the OS probability of mCRPC patients was significantly associated with plasma levels of alkaline phosphatase (hazard ratio [HR], 1.90; < 0.001), plasma levels of lactate dehydrogenase (HR, 1.01; < 0.001), hemoglobin levels (HR, 0.80; = 0.013), whole-body SUV (HR, 1.14; < 0.001), the number of F-FDG-avid metastases (HR, 1.08; < 0.001), whole-body metabolic tumor volume (HR, 1.86; < 0.001), and TLG (HR, 1.84; < 0.001). On multivariable analysis with stepwise variable selection, hemoglobin levels (HR, 0.81; = 0.013) and whole-body TLG (HR, 1.88; < 0.001) were independently associated with OS. In mCSPC patients, no significant association was observed between these variables and OS. In patients with mCRPC receiving first-line treatment with abiraterone or enzalutamide, F-FDG PET WB TLG is independently associated with OS and might be used as a quantitative prognostic imaging biomarker.

Citing Articles

Analysis of Molecular Imaging Biomarkers Derived from [F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [Ac]Ac-PSMA-617-Augmented [Lu]Lu-PSMA-617 Radioligand Therapy.

Burgard C, Khreish F, Dahlmanns L, Blickle A, Bastian M, Speicher T Cancers (Basel). 2024; 16(20).

PMID: 39456626 PMC: 11506772. DOI: 10.3390/cancers16203532.

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.

Chrenkova E, Studentova H, Hola K, Kahounova Z, Hendrychova R, Soucek K Front Oncol. 2024; 14:1394292.

PMID: 39319053 PMC: 11420116. DOI: 10.3389/fonc.2024.1394292.

A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.

Uo T, Ojo K, Sprenger C, Epilepsia K, Perera B, Damodarasamy M Mol Cancer Ther. 2024; 23(7):973-994.

PMID: 38507737 PMC: 11219269. DOI: 10.1158/1535-7163.MCT-23-0540.

Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.

Wang Y, Li Y, Jiang H, Zuo C, Xu W Br J Radiol. 2024; 97(1153):237-248.

PMID: 38263821 PMC: 11027281. DOI: 10.1093/bjr/tqad015.

Deep learning-based whole-body characterization of prostate cancer lesions on [Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence.

Huang B, Yang Q, Li X, Wu Y, Liu Z, Pan Z Eur J Nucl Med Mol Imaging. 2023; 51(4):1173-1184.

PMID: 38049657 DOI: 10.1007/s00259-023-06551-3.

References

Shukla-Dave A, Obuchowski N, Chenevert T, Jambawalikar S, Schwartz L, Malyarenko D . Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2018; 49(7):e101-e121. PMC: 6526078. DOI: 10.1002/jmri.26518. View

Shah B, Srivastava N, Hirsch A, Mercier G, Subramaniam R . Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. Ann Nucl Med. 2012; 26(9):707-14. DOI: 10.1007/s12149-012-0630-3. View

Meirelles G, Schoder H, Ravizzini G, Gonen M, Fox J, Humm J . Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010; 16(24):6093-9. PMC: 3402086. DOI: 10.1158/1078-0432.CCR-10-1357. View

Liu I, Zafar M, Lai Y, Segall G, Terris M . Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001; 57(1):108-11. DOI: 10.1016/s0090-4295(00)00896-7. View

Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A . Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review. Diagnostics (Basel). 2018; 8(3). PMC: 6163267. DOI: 10.3390/diagnostics8030045. View

Vargas H, Wassberg C, Fox J, Wibmer A, Goldman D, Kuk D . Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014; 271(1):220-9. PMC: 4263648. DOI: 10.1148/radiol.13130625. View

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

Jadvar H, Velez E, Desai B, Ji L, Colletti P, Quinn D . Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with F-FDG PET/CT. J Nucl Med. 2019; 60(11):1524-1530. PMC: 6836859. DOI: 10.2967/jnumed.118.223263. View

Boellaard R, Delgado-Bolton R, Oyen W, Giammarile F, Tatsch K, Eschner W . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014; 42(2):328-54. PMC: 4315529. DOI: 10.1007/s00259-014-2961-x. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Mhlanga J, Chirindel A, Lodge M, Wahl R, Subramaniam R . Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms. Nucl Med Commun. 2017; 39(2):154-160. DOI: 10.1097/MNM.0000000000000786. View

12.

Guinney J, Wang T, Laajala T, Kanigel Winner K, Bare J, Chaibub Neto E . Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2016; 18(1):132-142. PMC: 5217180. DOI: 10.1016/S1470-2045(16)30560-5. View

13.

Laffon E, de Clermont H, Lamare F, Marthan R . Variability of total lesion glycolysis by 18F-FDG-positive tissue thresholding in lung cancer. J Nucl Med Technol. 2013; 41(3):186-91. DOI: 10.2967/jnmt.113.122952. View

14.

Kramer G, Frings V, Hoetjes N, Hoekstra O, Smit E, de Langen A . Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2016; 57(9):1343-9. DOI: 10.2967/jnumed.115.170225. View

15.

Vargas H, Martin-Malburet A, Takeda T, Corradi R, Eastham J, Wibmer A . Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?. Urol Oncol. 2016; 34(11):482.e5-482.e10. PMC: 5097681. DOI: 10.1016/j.urolonc.2016.05.026. View

16.

Gravis G, Boher J, Fizazi K, Joly F, Priou F, Marino P . Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Eur Urol. 2014; 68(2):196-204. DOI: 10.1016/j.eururo.2014.09.022. View

17.

Jadvar H, Desai B, Ji L, Conti P, Dorff T, Groshen S . Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013; 54(8):1195-201. PMC: 3783857. DOI: 10.2967/jnumed.112.114116. View

18.

Larson S, Erdi Y, Akhurst T, Mazumdar M, Macapinlac H, Finn R . Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 2003; 2(3):159-171. DOI: 10.1016/s1095-0397(99)00016-3. View

19.

Paidpally V, Mercier G, Shah B, Senthamizhchelvan S, Subramaniam R . Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. AJR Am J Roentgenol. 2014; 202(2):406-12. DOI: 10.2214/AJR.13.10841. View

20.

Blanc-Durand P, Jegou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodere F . Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2020; 48(5):1362-1370. DOI: 10.1007/s00259-020-05080-7. View